MX370397B - Vacuna para enfermedad intrauterina. - Google Patents

Vacuna para enfermedad intrauterina.

Info

Publication number
MX370397B
MX370397B MX2015006862A MX2015006862A MX370397B MX 370397 B MX370397 B MX 370397B MX 2015006862 A MX2015006862 A MX 2015006862A MX 2015006862 A MX2015006862 A MX 2015006862A MX 370397 B MX370397 B MX 370397B
Authority
MX
Mexico
Prior art keywords
compositions
pyogenes
whole cells
necrophorum
coli
Prior art date
Application number
MX2015006862A
Other languages
English (en)
Other versions
MX2015006862A (es
Inventor
Carvalho Bicalho Rodrigo
Owen Gilbert Robert
Machado Vinicius
Bicalho Marcela
Original Assignee
Univ Cornell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cornell filed Critical Univ Cornell
Publication of MX2015006862A publication Critical patent/MX2015006862A/es
Publication of MX370397B publication Critical patent/MX370397B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/18—Arrangements for indicating condition of container contents, e.g. sterile condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/114—Fusobacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

La presente invención se refiere a una composición veterinaria para usarse para la profilaxis de metritis puerperal en un rumiante, en donde la composición veterinaria está formulada para ser administrable por vía subcutánea al mamífero rumiante, la composición veterinaria comprende la proteína leucotoxina (LKT) de F. necrophorum, la proteína adhesina fimbrial (FimH) de E.coli tipo 1, y la proteína piolisina de T.pyogenes (PLO).
MX2015006862A 2012-11-29 2013-10-08 Vacuna para enfermedad intrauterina. MX370397B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261731333P 2012-11-29 2012-11-29
PCT/US2013/063866 WO2014084964A1 (en) 2012-11-29 2013-10-08 Vaccine for intrauterine disease

Publications (2)

Publication Number Publication Date
MX2015006862A MX2015006862A (es) 2016-06-29
MX370397B true MX370397B (es) 2019-12-11

Family

ID=50828340

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015006862A MX370397B (es) 2012-11-29 2013-10-08 Vacuna para enfermedad intrauterina.
MX2019012044A MX2019012044A (es) 2012-11-29 2015-05-29 Vacuna para enfermedad intrauterina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019012044A MX2019012044A (es) 2012-11-29 2015-05-29 Vacuna para enfermedad intrauterina.

Country Status (12)

Country Link
US (4) US9533034B2 (es)
EP (2) EP3545970A1 (es)
JP (1) JP6301945B2 (es)
AU (1) AU2013353403B2 (es)
BR (3) BR122019025362B1 (es)
CA (1) CA2893072C (es)
ES (1) ES2718491T3 (es)
HU (1) HUE043129T2 (es)
MX (2) MX370397B (es)
NZ (2) NZ754388A (es)
RU (1) RU2672589C2 (es)
WO (1) WO2014084964A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ754388A (en) 2012-11-29 2022-05-27 Univ Cornell Vaccine for intrauterine disease
JP6570648B2 (ja) * 2015-03-12 2019-09-04 ゾエティス・サービシーズ・エルエルシー ピオリシン方法及び組成物
EP3373964A1 (en) 2015-11-09 2018-09-19 Epitopix, LLC Polypeptides of fusobacterium and methods of use
KR102474924B1 (ko) 2020-04-22 2022-12-06 영남대학교 산학협력단 대장균 부착 단백질 FimH를 유효성분으로 포함하는 항암 면역 증강용 조성물
WO2025093740A1 (en) 2023-11-03 2025-05-08 Intervet International B.V. Recombinant pyolysin protein
CN121405781B (zh) * 2025-12-29 2026-03-24 重庆市畜牧科学院 一种化脓隐秘杆菌表面蛋白及其筛选方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2186694T3 (es) * 1990-06-07 2003-05-16 Bayer Ag Vacuna bacteriana para el tratamiento de necrosis hepatica causada por f. necrophorum.
US5455034A (en) * 1992-06-26 1995-10-03 Kansas State University Research Foundation Fusobacterium necrophorum leukotoxoid vaccine
WO1994000556A1 (en) 1992-06-26 1994-01-06 Kansas State University Research Foundation Fusobacterium necrophorum leukotoxoid vaccine
ATE506074T1 (de) 1995-06-07 2011-05-15 Univ Kansas State Actinomyces pyogenes und actinomyces pyogenes/fusobakterium necrophorum impfstoffe zur immunisierung von vieh und schafen
US6669940B2 (en) * 2000-04-25 2003-12-30 Kansas University Research Foundation Recombinant fusobacterium necrophorum leukotoxin vaccine and preparation thereof
AU2002327338A1 (en) * 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
PE20050386A1 (es) * 2003-05-29 2005-06-23 Schering Plough Ltd Composiciones farmaceuticas de florfenicol
US9669060B2 (en) * 2009-04-23 2017-06-06 Cornell University Compositions for preventing and treating uterine disease
NZ754388A (en) * 2012-11-29 2022-05-27 Univ Cornell Vaccine for intrauterine disease

Also Published As

Publication number Publication date
EP2925353B1 (en) 2019-03-13
HUE043129T2 (hu) 2019-08-28
BR122019025365B1 (pt) 2022-07-26
EP3545970A1 (en) 2019-10-02
JP2016507479A (ja) 2016-03-10
US10821169B2 (en) 2020-11-03
ES2718491T3 (es) 2019-07-02
JP6301945B2 (ja) 2018-03-28
AU2013353403B2 (en) 2018-04-19
RU2015125646A (ru) 2017-01-10
US20170100473A1 (en) 2017-04-13
WO2014084964A1 (en) 2014-06-05
CA2893072A1 (en) 2014-06-05
NZ754388A (en) 2022-05-27
BR112015012288B1 (pt) 2022-07-26
CA2893072C (en) 2023-10-03
AU2013353403A1 (en) 2015-07-02
BR122019025362B1 (pt) 2022-07-26
US9533034B2 (en) 2017-01-03
US20150335725A1 (en) 2015-11-26
NZ708669A (en) 2019-12-20
MX2015006862A (es) 2016-06-29
RU2672589C2 (ru) 2018-11-16
BR112015012288A2 (pt) 2018-02-06
US20190358311A1 (en) 2019-11-28
EP2925353A1 (en) 2015-10-07
US9981032B2 (en) 2018-05-29
US20180236055A1 (en) 2018-08-23
EP2925353A4 (en) 2016-08-10
MX2019012044A (es) 2020-01-13

Similar Documents

Publication Publication Date Title
MX2019012044A (es) Vacuna para enfermedad intrauterina.
MX2019012081A (es) Proteina de fusion del factor de crecimiento 21 de fibroblastos humanos (hfgf21), metodo de preparacion de la misma y su uso.
CL2017001115A1 (es) Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf.
MY187047A (en) Selective pyy compounds and uses thereof
PH12018500284A1 (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
WO2015061416A3 (en) Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
MX2022006107A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
PH12015502792A1 (en) Crystalline bromodomain inhibitors
MX2017014083A (es) Polipeptido de fusion anti-cancer.
WO2015200514A3 (en) Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers
WO2012142511A3 (en) Orthomolecular compositions and their use in stabilizing the extracellular matrix
UA117103C2 (uk) Сполука, яка має активність агоніста глюкагону
WO2012069655A3 (en) Improved capping modules for designed ankyrin repeat proteins
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
IN2014DN06920A (es)
BR112012022223A2 (pt) formulações de proteína concentrada e usos das mesmas
PH12020550598A1 (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
MX2015000337A (es) Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles.
BR112018017031A2 (pt) formulações de antagonista de il-6 e usos das mesmas
MX370792B (es) Composiciones para usarse en el tratamiento de cáncer.
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
PH12014501991B1 (en) Phenicol antibacterials
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same

Legal Events

Date Code Title Description
FG Grant or registration